| Kimberly Rae Marble, MD | |
|
3 Alumni Dr, Ste 402, Exeter, NH 03833-2119 | |
| (603) 773-9904 | |
| (603) 773-9905 |
| Full Name | Kimberly Rae Marble |
|---|---|
| Gender | Female |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 25 Years |
| Location | 3 Alumni Dr, Exeter, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235187691 | NPI | - | NPPES |
| P00849476 | Other | NH | RAILROAD MEDICARE |
| 3076275 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | MD14955 (Maine) | Secondary |
| 208200000X | Plastic Surgery | 9816 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rockingham Vna And Hospice | Exeter, NH | Home health agency |
| Exeter Hospital Inc | Exeter, NH | Hospital |
| York Hospital | York, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Core Physicians Llc | 2769563253 | 234 |
| Core Physicians Llc | 2769563253 | 234 |
News Archive
A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.
The tidal wave approaches. In the coming decades, Alzheimer's disease is projected to exact a devastating economic and emotional toll on society, with patient numbers in the US alone expected to reach 13.5 million by mid-century at a projected cost of over a trillion dollars.
In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.
› Verified 8 days ago
| Entity Name | Core Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336330588 PECOS PAC ID: 2769563253 Enrollment ID: O20080123000205 |
News Archive
A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.
The tidal wave approaches. In the coming decades, Alzheimer's disease is projected to exact a devastating economic and emotional toll on society, with patient numbers in the US alone expected to reach 13.5 million by mid-century at a projected cost of over a trillion dollars.
In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Rae Marble, MD 7 Holland Way Fl 1, Exeter, NH 03833-2997 Ph: (603) 773-9904 | Kimberly Rae Marble, MD 3 Alumni Dr, Ste 402, Exeter, NH 03833-2119 Ph: (603) 773-9904 |
News Archive
A study on the impact of using different anticoagulation medications on men and women who have undergone a transcatheter aortic valve replacement (TAVR) found no difference in early vascular complications or mortality.
In the next five years, 11 million African women and children could be saved by creating near-universal availability of key life-saving interventions, according to The Partnership for Maternal, Newborn & Child Health and the Countdown to 2015 Decade Report (2000-2010).
NeoRx Corporation today announced that it has acquired from AnorMED Inc. the worldwide exclusive rights, excluding Japan, to develop, manufacture and commercialize AMD473, a platinum-based anti-cancer agent. AMD473 has been administered to more than 500 cancer patients in phase I and phase II clinical trials, demonstrating anti-cancer activity in a wide range of tumors and a manageable safety profile. NeoRx expects to initiate clinical studies of AMD473 in one or more cancer indications in the second half of this year.
The tidal wave approaches. In the coming decades, Alzheimer's disease is projected to exact a devastating economic and emotional toll on society, with patient numbers in the US alone expected to reach 13.5 million by mid-century at a projected cost of over a trillion dollars.
In honor of World Stroke Day (October 29, 2010), Coherex Medical, Inc. today announced it has achieved two milestones that further strengthen its position as an emerging medical device company in the field of structural heart disease.
› Verified 8 days ago